Table 1. Summary of KDIGO and American Diabetes Association (ADA) recommendations regarding surveillance among acute kidney injury, chronic kidney disease, and diabetic patient cohorts.

Clinical Setting	Laboratory Test(s)	Monitoring Recommendation
Acute Kidney Injury [47]	Serum Creatinine	3 months following AKI to assess for CKD:
		If CKD, use CKD monitoring recommendations
		If not CKD, consider as increased CKD risk
After Acute Kidney Injury without Chronic Kidney Disease [47]	Serum Creatinine, Any Urine Protein	Recommend undergoing testing to estimate renal function and markers of chronic kidney disease but do not specify an interval
Chronic Kidney Disease [15]	Serum Creatinine, Any Urine Protein, Urine Quantitative Protein	Every 12 months or every 4–6 months with GFR<30 or moderately increased proteinuria. Quantitative assessment preferred over dipstick urine protein.
Chronic Kidney Disease [15], [48]	Serum PTH, Serum Phosphate	Measurement at least once to establish baseline, with subsequent frequency of testing determined on an individual basis, with reasonable monitoring intervals every 12 months or every 3–6 months for GFR<30
Diabetes [49]	Urine Quantitative Protein	Every 12 months